Alivus Life Sciences posts record Q1 PAT, EBITDA margin hits 36.6%
Alivus Life Sciences posted record Q1FY27 profits with PAT rising 31.8% to ₹1,601 million and EBITDA margins hitting 36.6%. Non-GPL revenue growth offset GPL declines, while robust cash flows support significant capacity expansion plans.
*this image is generated using AI for illustrative purposes only.
Alivus Life Sciences reported its highest-ever quarterly net profit of ₹1,601 million for Q1FY27, ending June 30, 2026, marking a 31.8% year-on-year increase. The company’s earnings before interest, tax, depreciation, and amortization (EBITDA) surged 29.1% to ₹2,341 million, with margins expanding to a record high of 36.6%. This performance underscores the strength of its non-Generic Pharmaceutical Ingredient (non-GPL) portfolio, which grew 26.5% year-on-year, offsetting a significant decline in the GPL segment due to inventory rationalization.
Revenue from operations rose 6.4% to ₹6,404 million, supported by robust demand in chronic therapeutic areas such as cardiovascular disease and diabetes. The Board of Directors approved the unaudited financial results on July 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Walker ChandioK & Co LLP issued an unmodified review conclusion on the financial statements prepared under Indian Accounting Standards (Ind AS).
Financial Performance Overview
The profit after tax (PAT) margin improved by 480 basis points to 25.0% compared to the previous year. Total income stood at ₹6,628.15 million, while total expenses were ₹4,505.92 million. The company generated strong free cash flow of ₹901 million during the quarter, reinforcing its net debt-free position. As of June 30, 2026, Alivus held cash and cash equivalents, including short-term investments, of ₹8,802 million. Gross margins reached 60.2%, up 510 basis points year-on-year, driven by favorable product mix and new launches.
| Particulars | Q1FY27 (₹ Million) | Q1FY26 (₹ Million) | Change |
|---|---|---|---|
| Revenue from operations | 6,404 | 6,018 | +6.4% |
| EBITDA | 2,341 | 1,813 | +29.1% |
| Net Profit (PAT) | 1,601 | 1,215 | +31.8% |
| Cash & Equivalents | 8,802 | — | — |
Segmental and Operational Insights
Dr. Yasir Rawjee, Managing Director and CEO, attributed the results to resilient execution and accelerating traction in the non-GPL business. He noted that while the GPL business is expected to remain flattish in FY27 due to historical skew towards the second half, the company targets revenue growth of 10%–12% for the full year. CFO Tushar Mistry highlighted the sustainable nature of the margin expansion, driven by favorable product mix and successful new launches. The non-GPL segment contributed 88.7% of total revenue in Q1FY27, growing 27.6% quarter-on-quarter.
The company continues to invest in capacity expansion and pipeline development. Construction work for Phase 1 (350 KL capacity) and Phase 2 (115 KL capacity) at the Solapur facility is underway, with completion expected in Q3FY27 and Q4FY27, respectively. Additionally, brownfield expansions are planned for Ankleshwar (100 KL by Q4FY27) and Dahej (160 KL by Q3FY27). A new R&D facility in Taloja, Navi Mumbai, has begun construction to focus on flow chemistry, oncology research, and green chemistry. Cumulative Drug Master File (DMF) and Certificate of Suitability (CEP) filings have reached 617 as of June 30, 2026.
What the Numbers Show
The divergence between revenue growth (6.4%) and EBITDA growth (29.1%) signals significant operational leverage for Alivus Life Sciences in Q1FY27. The expansion of EBITDA margins to 36.6%, the highest on record, indicates that cost controls and product mix shifts are outpacing input cost inflation. Furthermore, the generation of ₹901 million in free cash flow alongside a ₹8,802 million cash balance provides substantial financial flexibility to fund ongoing capex projects without external debt, reducing financial risk as the company scales its high-value API portfolio. The return on invested capital (ROICE) tracked at ~32%, reflecting efficient capital deployment despite the ongoing capex cycle.
Historical Stock Returns for Alivus Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.13% | -3.75% | -2.13% | +16.56% | +7.78% | +46.39% |
How might the completion of the Solapur and Ankleshwar capacity expansions in late FY27 impact Alivus's ability to capture market share in high-value non-GPL APIs?
Given the significant decline in the GPL segment, what specific strategies is Alivus employing to stabilize this business line for the second half of FY27?
Will the new R&D facility in Taloja focusing on flow chemistry and green chemistry provide a competitive moat against emerging API manufacturers in Asia?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
